Moffitt Cancer Center

Magnolia Campus

Tampa, FL

Accepting patients

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2

Accepting patients

ADVANCE

A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Not yet accepting

KarMMa-9

A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Learn more
  • CAR T Cell
  • Immunomodulatory Drug
  • BCMA
  • Randomization
  • Phase 3

Not yet accepting

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1

Not currently accepting

CARTITUDE-2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2
  • Has results

Accepting patients

iMMAGINE-1

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Not currently accepting

EXCALIBER-Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Not currently accepting

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

ABBV-383

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 1
2 hidden based on your filters. Show All

Filters

Diagnosis

Treatment History

BCMA Therapy

Advanced Filters

Trial Enrollment Status

Classifications

Targets

Trial Type

Phase